[{"orgOrder":0,"company":"Midland Research Group","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Midland Research Group","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Midland Research Group \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"11","companyTruncated":"Midland Research Group \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Academisch Ziekenhuis Maastricht","sponsor":"The Netherlands Cancer Institute | ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"NETHERLANDS","productType":"Miscellaneous","year":"2019","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Oncology","graph2":"Phase I","graph3":"Academisch Ziekenhuis Maastricht","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Ziekenhuis Maastricht \/ The Netherlands Cancer Institute | ZonMw","highestDevelopmentStatusID":"6","companyTruncated":"Academisch Ziekenhuis Maastricht \/ The Netherlands Cancer Institute | ZonMw"},{"orgOrder":0,"company":"Fundacion SEIMC-GESIDA","sponsor":"Janssen-Cilag","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"SPAIN","productType":"Miscellaneous","year":"2018","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Fundacion SEIMC-GESIDA","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fundacion SEIMC-GESIDA \/ Janssen-Cilag","highestDevelopmentStatusID":"11","companyTruncated":"Fundacion SEIMC-GESIDA \/ Janssen-Cilag"},{"orgOrder":0,"company":"University of California, San Diego","sponsor":"University at Buffalo | Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"University of California, San Diego","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of California, San Diego \/ University at Buffalo | Gilead Sciences","highestDevelopmentStatusID":"1","companyTruncated":"University of California, San Diego \/ University at Buffalo | Gilead Sciences"},{"orgOrder":0,"company":"Midtown Medical Center, Tampa","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2015","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Midtown Medical Center, Tampa","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Midtown Medical Center, Tampa \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"Midtown Medical Center, Tampa \/ Gilead Sciences"},{"orgOrder":0,"company":"University of Hawaii","sponsor":"Gilead Sciences","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Hawaii","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Hawaii \/ Gilead Sciences","highestDevelopmentStatusID":"11","companyTruncated":"University of Hawaii \/ Gilead Sciences"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2010","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Johnson & Johnson Innovative Medicine","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Johnson & Johnson Innovative Medicine","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Johnson & Johnson Innovative Medicine"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Gilead Sciences","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Cobicistat","moa":"Cytochrome P450 3A","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Gilead Sciences","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Gilead Sciences \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Gilead Sciences \/ Undisclosed"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"INDIA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Lupin Ltd \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Johnson & Johnson","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Darunavir","moa":"||Human immunodeficiency virus type 1 protease","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Johnson & Johnson","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Johnson & Johnson \/ Undisclosed","highestDevelopmentStatusID":"1","companyTruncated":"Johnson & Johnson \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Goldman Sachs & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2022","type":"Public Offering","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Syndax Pharmaceuticals","amount2":0.17000000000000001,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0.17000000000000001,"dosageForm":"Capsule","sponsorNew":"Syndax Pharmaceuticals \/ Goldman Sachs & Co","highestDevelopmentStatusID":"7","companyTruncated":"Syndax Pharmaceuticals \/ Goldman Sachs & Co"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Syndax Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2024","type":"Inapplicable","leadProduct":"Revumenib","moa":"||Menin\/Histone-lysine N-methyltransferase MLL","graph1":"Oncology","graph2":"Approved FDF","graph3":"Syndax Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Syndax Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"Syndax Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2023","type":"Inapplicable","leadProduct":"Plixorafenib","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Fore Biotherapeutics","sponsor":"SR One","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Miscellaneous","year":"2025","type":"Series D Financing","leadProduct":"Plixorafenib","moa":"||Serine\/threonine-protein kinase B-raf","graph1":"Oncology","graph2":"Phase II","graph3":"Fore Biotherapeutics","amount2":0.11,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.11,"dosageForm":"Tablet","sponsorNew":"Fore Biotherapeutics \/ SR One","highestDevelopmentStatusID":"8","companyTruncated":"Fore Biotherapeutics \/ SR One"}]
Find Clinical Drug Pipeline Developments & Deals for Cobicistat
Filters
×
FILTER:
Company Name
Year
DEALS // DEV.
Country
Sponsor
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Reset All
